Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu- CC49

A phase I/II study

Ronald D. Alvarez, Edward E. Partridge, M. B. Khazaeli, Gene Plott, Max Austin, Larry Kilgore, Charles D. Russell, Tiepu Liu, William E. Grizzle, Jeffrey Schlom, Albert F. LoBuglio, Ruby F. Meredith

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

Background. Twenty-seven ovarian cancer patients who failed chemotherapy entered a phase I/II trial of intraperitoneal 177Lu-CC49 antibody. Methods. Patients had disease confined to the abdominal cavity ± retroperitoneal lymph nodes, adequate organ function, and no previous radiation. Results. The most common side effects were delayed, transient arthralgia (10/27) and marrow suppression with 1.665 GBq/m2 (45 mCi/m2), which was considered the maximum tolerated dose. One of thirteen patients with gross disease had >50% tumor reduction after therapy, whereas most others with gross disease progressed (one went off study with stable disease at 11 weeks). Seven of nine patients with <1-cm nodules progressed in ≤21 months, and two of nine remain without evidence of disease at 4 to 5 months. Of patients with microscopic or occult disease, one relapsed at 10 months and four of five remain without evidence of disease at >6 to 35 months. Conclusions. Marrow suppression was the dose-limiting toxic effect of intraperitoneal immunotherapy with 177Lu-CC49. Antitumor effects were noted against chemotherapy-resistant ovarian cancer, even at lower dose levels, and resulted in prolonged disease-free survival of most patients with microscopic disease. This form of treatment deserves further study.

Original languageEnglish (US)
Pages (from-to)94-101
Number of pages8
JournalGynecologic oncology
Volume65
Issue number1
DOIs
StatePublished - Jan 1 1997

Fingerprint

Radioimmunotherapy
Ovarian Neoplasms
Bone Marrow
Drug Therapy
Maximum Tolerated Dose
Abdominal Cavity
Poisons
Arthralgia
Immunotherapy
Disease-Free Survival
Lymph Nodes
Radiation
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Alvarez, R. D., Partridge, E. E., Khazaeli, M. B., Plott, G., Austin, M., Kilgore, L., ... Meredith, R. F. (1997). Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu- CC49: A phase I/II study. Gynecologic oncology, 65(1), 94-101. https://doi.org/10.1006/gyno.1996.4577

Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu- CC49 : A phase I/II study. / Alvarez, Ronald D.; Partridge, Edward E.; Khazaeli, M. B.; Plott, Gene; Austin, Max; Kilgore, Larry; Russell, Charles D.; Liu, Tiepu; Grizzle, William E.; Schlom, Jeffrey; LoBuglio, Albert F.; Meredith, Ruby F.

In: Gynecologic oncology, Vol. 65, No. 1, 01.01.1997, p. 94-101.

Research output: Contribution to journalArticle

Alvarez, RD, Partridge, EE, Khazaeli, MB, Plott, G, Austin, M, Kilgore, L, Russell, CD, Liu, T, Grizzle, WE, Schlom, J, LoBuglio, AF & Meredith, RF 1997, 'Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu- CC49: A phase I/II study', Gynecologic oncology, vol. 65, no. 1, pp. 94-101. https://doi.org/10.1006/gyno.1996.4577
Alvarez, Ronald D. ; Partridge, Edward E. ; Khazaeli, M. B. ; Plott, Gene ; Austin, Max ; Kilgore, Larry ; Russell, Charles D. ; Liu, Tiepu ; Grizzle, William E. ; Schlom, Jeffrey ; LoBuglio, Albert F. ; Meredith, Ruby F. / Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu- CC49 : A phase I/II study. In: Gynecologic oncology. 1997 ; Vol. 65, No. 1. pp. 94-101.
@article{5e6dea4f21d543af8eb4b23eeda9d255,
title = "Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu- CC49: A phase I/II study",
abstract = "Background. Twenty-seven ovarian cancer patients who failed chemotherapy entered a phase I/II trial of intraperitoneal 177Lu-CC49 antibody. Methods. Patients had disease confined to the abdominal cavity ± retroperitoneal lymph nodes, adequate organ function, and no previous radiation. Results. The most common side effects were delayed, transient arthralgia (10/27) and marrow suppression with 1.665 GBq/m2 (45 mCi/m2), which was considered the maximum tolerated dose. One of thirteen patients with gross disease had >50{\%} tumor reduction after therapy, whereas most others with gross disease progressed (one went off study with stable disease at 11 weeks). Seven of nine patients with <1-cm nodules progressed in ≤21 months, and two of nine remain without evidence of disease at 4 to 5 months. Of patients with microscopic or occult disease, one relapsed at 10 months and four of five remain without evidence of disease at >6 to 35 months. Conclusions. Marrow suppression was the dose-limiting toxic effect of intraperitoneal immunotherapy with 177Lu-CC49. Antitumor effects were noted against chemotherapy-resistant ovarian cancer, even at lower dose levels, and resulted in prolonged disease-free survival of most patients with microscopic disease. This form of treatment deserves further study.",
author = "Alvarez, {Ronald D.} and Partridge, {Edward E.} and Khazaeli, {M. B.} and Gene Plott and Max Austin and Larry Kilgore and Russell, {Charles D.} and Tiepu Liu and Grizzle, {William E.} and Jeffrey Schlom and LoBuglio, {Albert F.} and Meredith, {Ruby F.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1006/gyno.1996.4577",
language = "English (US)",
volume = "65",
pages = "94--101",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu- CC49

T2 - A phase I/II study

AU - Alvarez, Ronald D.

AU - Partridge, Edward E.

AU - Khazaeli, M. B.

AU - Plott, Gene

AU - Austin, Max

AU - Kilgore, Larry

AU - Russell, Charles D.

AU - Liu, Tiepu

AU - Grizzle, William E.

AU - Schlom, Jeffrey

AU - LoBuglio, Albert F.

AU - Meredith, Ruby F.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Background. Twenty-seven ovarian cancer patients who failed chemotherapy entered a phase I/II trial of intraperitoneal 177Lu-CC49 antibody. Methods. Patients had disease confined to the abdominal cavity ± retroperitoneal lymph nodes, adequate organ function, and no previous radiation. Results. The most common side effects were delayed, transient arthralgia (10/27) and marrow suppression with 1.665 GBq/m2 (45 mCi/m2), which was considered the maximum tolerated dose. One of thirteen patients with gross disease had >50% tumor reduction after therapy, whereas most others with gross disease progressed (one went off study with stable disease at 11 weeks). Seven of nine patients with <1-cm nodules progressed in ≤21 months, and two of nine remain without evidence of disease at 4 to 5 months. Of patients with microscopic or occult disease, one relapsed at 10 months and four of five remain without evidence of disease at >6 to 35 months. Conclusions. Marrow suppression was the dose-limiting toxic effect of intraperitoneal immunotherapy with 177Lu-CC49. Antitumor effects were noted against chemotherapy-resistant ovarian cancer, even at lower dose levels, and resulted in prolonged disease-free survival of most patients with microscopic disease. This form of treatment deserves further study.

AB - Background. Twenty-seven ovarian cancer patients who failed chemotherapy entered a phase I/II trial of intraperitoneal 177Lu-CC49 antibody. Methods. Patients had disease confined to the abdominal cavity ± retroperitoneal lymph nodes, adequate organ function, and no previous radiation. Results. The most common side effects were delayed, transient arthralgia (10/27) and marrow suppression with 1.665 GBq/m2 (45 mCi/m2), which was considered the maximum tolerated dose. One of thirteen patients with gross disease had >50% tumor reduction after therapy, whereas most others with gross disease progressed (one went off study with stable disease at 11 weeks). Seven of nine patients with <1-cm nodules progressed in ≤21 months, and two of nine remain without evidence of disease at 4 to 5 months. Of patients with microscopic or occult disease, one relapsed at 10 months and four of five remain without evidence of disease at >6 to 35 months. Conclusions. Marrow suppression was the dose-limiting toxic effect of intraperitoneal immunotherapy with 177Lu-CC49. Antitumor effects were noted against chemotherapy-resistant ovarian cancer, even at lower dose levels, and resulted in prolonged disease-free survival of most patients with microscopic disease. This form of treatment deserves further study.

UR - http://www.scopus.com/inward/record.url?scp=0031127626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031127626&partnerID=8YFLogxK

U2 - 10.1006/gyno.1996.4577

DO - 10.1006/gyno.1996.4577

M3 - Article

VL - 65

SP - 94

EP - 101

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -